In a fresh sign that the big biotech IPO wave that triggered a long lineup of dazzling debuts may have crested, two new California contenders have had to significantly scale down their expectations and a third has decided to bow out for now.
Fresh off posting some positive Phase III results for its lead drug, California's Relypsa has scaled-up its proposed IPO, seeking $138 million to carry it toward FDA approval.
Just weeks away from reporting key endpoint data from a Phase III trial of its lead therapy, Relypsa has mapped out plans to go public, shooting for a $126.5 million payday to help complete a prospective transformative leap into marketing.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...
The money--which follows a $70 million round two years ago--will be used to put RLY5016 to the ultimate test as a treatment for hyperkalemia, a condition in which high levels of potassium threatens patients suffering from diabetes, heart failure, and kidney disease with a potentially lethal case of arrhythmia.
Two years after an experienced team of biotech executives gathered a whopping $70 million venture round for Relypsa, the Santa Clara, CA-based developer is almost $50 million closer to another big round of financing, according to SEC documents.
Relypsa, the start-up biotech born out of Amgen's acquisition of Ilypsa, has rounded up a whopping $70 million for its Series B, bringing its venture haul to more than $100 million. Santa Clara,